EJPMR, 2026, 13(5), 129-133 **Review Article** **Impact Factor: 8.158**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

REVIEW ON PULSATILE DRUG DELIVERY SYSTEM

[1]*Prof. Abhishek Subhash Narwade, [2]S. Nilesh Vishnu Rasal, [2]S. Yash Sanjay Balkhande, [2]S. Khushal Bhikamchand Kantale, [2]S. Gopal Purushottam Khandagale, [2]S. Prajwal Nilkanth Chandanngole, [2]Dr. Nandu Kayande

[1]Assistant Professor, Department of Pharmacy, Dr. R.N.Lahoti Institute of Pharmaceutical Education and Research Center Jalna Road, Sultanpur Tq: Lonar Dist: Buldhana, Maharashtra 443302.
[2]UG Student, Department of Pharmacy, Dr. R.N.Lahoti Institute of Pharmaceutical Education and Research Center Jalna Road, Sultanpur Tq: Lonar Dist: Buldhana, Maharashtra 443302.

***Corresponding Author: Prof. Abhishek Subhash Narwade**

Assistant Professor, Department of Pharmacy, Dr. R.N.Lahoti Institute of Pharmaceutical Education and Research Center Jalna Road, Sultanpur Tq: Lonar Dist: Buldhana, Maharashtra 443302.

DOI: https://doi.org/10.5281/zenodo.19884173

How to cite this Article: [1]*Prof. Abhishek Subhash Narwade, [2]S. Nilesh Vishnu Rasal, [2]S. Yash Sanjay Balkhande, [2]S. Khushal Bhikamchand Kantale, [2]S. Gopal Purushottam Khandagale, [2]S. Prajwal Nilkanth Chandanngole, [2]Dr Nandu Kayande. (2026). Review On Pulsatile Drug Delivery System. European Journal of Biomedical and Pharmaceutical Sciences, 13(5), 129–133.

Article Received on 31/03/2026 **Article Revised on 22/04/2026** **Article Published on 01/05/2026**

ABSTRACT
Pulsatile drug delivery systems (PDDS) are advanced pharmaceutical formulations designed to release drugs in a time-controlled manner, characterized by a distinct lag phase followed by rapid drug release. Unlike conventional sustained-release systems, PDDS are developed to synchronize drug availability with the body's biological rhythms, an approach closely associated with Chronopharmacology. This targeted delivery is particularly beneficial in managing diseases that exhibit circadian variation in symptoms and severity.The design of pulsatile systems involves various strategies, including time-dependent coatings, stimuli-responsive mechanisms, and externally regulated devices. These systems can be triggered by physiological factors such as pH, enzymes, or temperature, ensuring site-specific and timely drug release. PDDS have shown significant therapeutic advantages in conditions like Asthma, Hypertension, and Rheumatoid Arthritis, where symptoms follow predictable daily patterns.Recent advancements in polymer science, nanotechnology, and smart drug delivery have enhanced the precision and efficiency of pulsatile systems. Despite these benefits, challenges such as complex manufacturing processes, higher costs, and potential variability in drug release remain significant concerns.In conclusion, pulsatile drug delivery systems offer a promising approach to improving therapeutic outcomes by aligning drug release with physiological needs. Continued research and technological innovation are expected to overcome current limitations and expand their clinical applications, making PDDS an important focus in modern pharmaceutics.

KEYWORDS: Pulsatile release, lag time delivery, chronotherapy, time-dependent systems, controlled drug release, stimuli-responsive systems, circadian rhythm targeting, site-specific delivery, smart drug carriers, delayed release formulations.

INTRODUCTION
Pulsatile Drug Delivery Systems (PDDS) represent a significant evolution in the field of pharmaceutics, focusing on the precise timing of drug release to match the body's physiological needs. Traditional drug delivery methods, such as immediate-release and sustained-release formulations, are designed to maintain consistent drug levels in the bloodstream over an extended period. While these approaches have proven beneficial in many therapeutic areas, they often fail to address the dynamic nature of human biology, where numerous physiological processes and disease conditions follow predictable temporal patterns. This limitation has led to the development of more sophisticated delivery strategies, among which pulsatile systems have gained considerable attention.

The fundamental concept behind pulsatile drug delivery is the release of a drug after a predetermined lag time, followed by a rapid and complete release of the active ingredient. This pattern mimics the body's natural rhythms and ensures that the drug is available at the time it is most needed. The scientific basis of this approach is closely linked to Chronopharmacology, which studies how the effects of drugs change according to biological timing and circadian rhythms. By aligning drug release with these rhythms, PDDS can enhance therapeutic efficacy while minimizing adverse effects.

Human physiological functions, including hormone secretion, enzyme activity, gastric pH, and blood pressure, often follow circadian rhythms. For example, cortisol levels peak in the early morning, while melatonin secretion increases during the night. Similarly, certain diseases exhibit time-dependent patterns in their symptoms. Conditions such as Asthma tend to worsen during the night or early morning hours, while Hypertension often shows a morning surge in blood pressure. In the case of Rheumatoid Arthritis, patients frequently experience increased joint stiffness and pain upon waking. Conventional drug delivery systems, which release drugs continuously, may not provide optimal therapeutic outcomes in such cases, as they do not account for these fluctuations. Pulsatile systems, on the other hand, are specifically designed to address these variations by delivering the drug at the most appropriate time.

The design and development of PDDS involve a range of innovative approaches and technologies. One common strategy is the use of time-controlled systems, where the drug is coated with polymers that dissolve or erode after a specific period. This creates a lag phase before the drug is released. Another approach involves stimuli-responsive systems, which release the drug in response to internal triggers such as pH changes, enzymatic activity, or temperature variations. For instance, pH-sensitive systems can be used to target drug release in specific regions of the gastrointestinal tract, such as the colon, where the pH differs from that of the stomach. Enzyme-responsive systems take advantage of the presence of specific enzymes in certain tissues or organs to trigger drug release.

Externally regulated pulsatile systems represent another innovative category, where drug release is controlled by external stimuli such as magnetic fields, ultrasound, or light. These systems offer a high degree of control and can be particularly useful in specialized therapeutic applications. However, their complexity and cost may limit their widespread use.

A variety of dosage forms have been developed to achieve pulsatile drug delivery. These include press-coated tablets, osmotic systems, capsule-based systems, and multiparticulate formulations. Press-coated tablets consist of a core containing the drug, surrounded by a barrier layer that delays release. Osmotic systems use osmotic pressure to control the timing of drug release, while capsule-based systems may contain a plug or barrier that is removed or dissolved after a certain period. Multiparticulate systems, such as pellets or beads, offer additional flexibility and can provide more consistent and predictable drug release profiles.

The materials used in PDDS play a crucial role in determining their performance. Polymers are widely used due to their versatility and ability to respond to various stimuli. Both natural and synthetic polymers can be employed, depending on the desired characteristics of the system. Biodegradable polymers are particularly advantageous, as they can break down into non-toxic byproducts within the body. Advances in polymer science have led to the development of smart polymers, which can change their properties in response to environmental conditions, further enhancing the capabilities of pulsatile systems.

Despite their many advantages, pulsatile drug delivery systems also present several challenges. The design and manufacturing processes are often complex and require precise control over multiple variables. Achieving a consistent lag time and ensuring reliable drug release can be difficult, particularly when scaling up production. Additionally, the cost of developing and producing these systems is generally higher than that of conventional formulations. There is also a risk of dose dumping, where a large amount of drug is released due to system failure, potentially leading to adverse effects.

Regulatory considerations add another layer of complexity to the development of PDDS. These systems must meet stringent requirements for safety, efficacy, and quality, and their novel mechanisms of action may require additional testing and validation. Furthermore, patient compliance and acceptance are important factors to consider, as more complex dosage forms may be less convenient or more difficult to use.

In recent years, significant progress has been made in overcoming these challenges through advances in technology and a better understanding of biological systems. Nanotechnology has opened new possibilities for the development of highly precise and targeted pulsatile systems. Nanocarriers can be engineered to respond to specific stimuli and deliver drugs with a high degree of accuracy. Additionally, the integration of PDDS with personalized medicine approaches holds great promise. By tailoring drug delivery systems to individual patients based on their unique biological rhythms and disease patterns, it may be possible to achieve even greater therapeutic benefits.

Another important area of research is the development of multi-pulsatile systems, which can deliver multiple doses of a drug at different times. This approach is particularly useful for conditions that require repeated dosing or where multiple peaks in drug concentration are needed. Advances in computational modeling and simulation have also contributed to the design and optimization of PDDS, allowing researchers to predict and control drug release profiles more effectively.

The future of pulsatile drug delivery systems is closely tied to ongoing innovations in materials science, biotechnology, and data analytics. As our understanding of circadian biology and disease mechanisms continues to grow, new opportunities will emerge for the application of PDDS in a wide range of therapeutic areas. The integration of digital health technologies, such as wearable devices and sensors, may further enhance the ability to monitor and adjust drug delivery in real time.

In conclusion, pulsatile drug delivery systems represent a promising and rapidly evolving area of pharmaceutical research. By focusing on the timing of drug release and aligning it with the body's natural rhythms, these systems offer a more targeted and effective approach to therapy. Although challenges remain in terms of design, manufacturing, and cost, ongoing advancements are expected to address these issues and expand the clinical applications of PDDS. As a result, pulsatile drug delivery is likely to play an increasingly important role in the future of medicine, contributing to improved patient outcomes and more efficient use of therapeutic agents.

MATERIALS AND METHODS

The development of Pulsatile Drug Delivery Systems (PDDS) requires a systematic selection of materials and carefully designed methodologies to achieve the desired lag time followed by rapid drug release. These systems are formulated based on the principles of Chronopharmacology, ensuring that drug release coincides with the body's circadian needs. The materials and methods used in PDDS are critical in determining the efficiency, reproducibility, and therapeutic performance of the formulation.

Materials

The selection of materials for pulsatile drug delivery is primarily based on their physicochemical properties, biocompatibility, and responsiveness to environmental stimuli. The major categories of materials used include active pharmaceutical ingredients, polymers, excipients, coating agents, and solvents.

Active Pharmaceutical Ingredients (APIs)

The drug chosen for PDDS should have a short half-life, significant first-pass metabolism, or a clear circadian pattern in disease management. Drugs used in the treatment of diseases such as Asthma, Hypertension, and Rheumatoid Arthritis are commonly incorporated into pulsatile systems. The physicochemical properties of the drug, including solubility, stability, and molecular weight, play a crucial role in formulation design.

Polymers

Polymers are the backbone of PDDS and are responsible for controlling the lag time and release profile. Both natural and synthetic polymers are used depending on the formulation requirements.

- **Natural polymers**: Examples include chitosan, alginate, and guar gum. These are biodegradable and biocompatible, making them suitable for colon-targeted delivery.
- **Synthetic polymers**: These include polymethacrylates, ethyl cellulose, and hydroxypropyl methylcellulose (HPMC). Synthetic polymers offer better control over drug release and mechanical strength.

  Polymers may function as swelling agents, erodible barriers, or rupturable coatings, depending on the system design.

Excipients

Excipients are added to improve the manufacturability and performance of the dosage form. Common excipients include:

- Fillers (lactose, microcrystalline cellulose)
- Binders (polyvinylpyrrolidone)
- Disintegrants (sodium starch glycolate)
- Lubricants (magnesium stearate)

These components ensure proper tablet formation and influence drug release characteristics.

Coating Agents

Coating materials are essential in creating the lag phase. These include:

- pH-sensitive polymers (e.g., Eudragit series)
- Water-insoluble polymers (e.g., ethyl cellulose)
- Enteric coatings

The thickness and composition of the coating determine the duration of the lag time before drug release.

Solvents and Plasticizers

Solvents such as ethanol, isopropyl alcohol, and water are used during the coating process. Plasticizers like polyethylene glycol and dibutyl phthalate are added to improve film flexibility and prevent cracking.

Methods

The preparation of pulsatile drug delivery systems involves various formulation techniques depending on the desired release mechanism. These methods are broadly classified into time-controlled, stimuli-responsive, and externally regulated systems.

1. Time-Controlled Systems

a) Press-Coated Tablets

This method involves compressing a core tablet containing the drug, followed by coating it with a layer of polymeric material. The outer layer acts as a barrier that erodes or ruptures after a specific time.

Procedure

- The core tablet is prepared using direct compression or wet granulation.
- The coating layer is applied using compression coating techniques.
- The thickness of the coating is optimized to achieve the desired lag time.

b) Capsule-Based Systems (Pulsincap)
In this method, a water-insoluble capsule body is filled with the drug and sealed with a hydrogel plug.

Procedure
- The drug is filled into a capsule body.
- A polymeric plug is inserted to block the opening.
- The capsule is coated with a water-soluble or enteric layer.
- Upon contact with gastrointestinal fluids, the plug swells or dissolves, releasing the drug.

c) Osmotic Systems
Osmotic pressure is used to control drug release after a lag time.

Procedure
- The drug core is coated with a semi-permeable membrane.
- A small orifice is drilled into the coating.
- Water enters the system, generating pressure that eventually forces the drug out.

2. Stimuli-Responsive Systems
These systems rely on physiological triggers for drug release.

a) pH-Sensitive Systems
Designed to release drugs at specific pH conditions, such as in the colon.

Method
- The drug is coated with pH-sensitive polymers that dissolve at higher pH levels.
- The formulation remains intact in the stomach but releases the drug in the intestine or colon.

b) Enzyme-Triggered Systems
These systems utilize enzymes present in specific regions of the body.

Method
- The drug is embedded in a polymer matrix that is degraded by enzymes.
- The degradation leads to drug release at the target site.

c) Temperature-Sensitive Systems
These systems respond to changes in temperature.

Method
- Thermo-responsive polymers are used, which undergo phase transitions at specific temperatures.
- Drug release occurs when the polymer structure changes.

3. Multiparticulate Systems
Multiparticulate systems consist of multiple small units such as pellets, beads, or granules.

Preparation Methods
- Extrusion-spheronization
- Layering techniques
- Spray drying

These systems are coated individually to achieve pulsatile release and offer advantages such as reduced risk of dose dumping and improved reproducibility.

4. Evaluation Methods
To ensure the quality and performance of PDDS, various evaluation techniques are employed.

a) Preformulation Studies
- Determination of drug solubility, stability, and compatibility with excipients
- Fourier Transform Infrared Spectroscopy (FTIR)
- Differential Scanning Calorimetry (DSC)

b) In Vitro Dissolution Studies
- Conducted using dissolution apparatus
- Simulated gastrointestinal fluids are used
- Measurement of lag time and release profile

c) Physical Characterization
- Tablet hardness and friability
- Thickness and weight variation
- Coating uniformity

d) Swelling and Erosion Studies
- Measurement of polymer swelling index
- Determination of erosion rate

e) In Vivo Studies
- Animal models or human studies to evaluate pharmacokinetics
- Assessment of drug release timing and therapeutic efficacy

5. Statistical Analysis
Experimental data are analyzed using statistical tools to ensure reproducibility and reliability. Parameters such as mean, standard deviation, and release kinetics are evaluated. Mathematical models like zero-order, first-order, and Higuchi models are applied to understand drug release mechanisms.

CONCLUSION
Pulsatile Drug Delivery Systems (PDDS) have emerged as a highly promising and innovative approach in modern pharmaceutics, offering a distinct advantage over conventional drug delivery methods by focusing on the precise timing of drug release. Unlike traditional sustained or controlled-release systems that maintain constant drug levels in the bloodstream, PDDS are specifically designed to release drugs after a defined lag time, followed by a rapid and targeted release. This unique mechanism allows for better synchronization with the body's biological rhythms, a concept strongly associated with Chronopharmacology.One of the most

significant benefits of pulsatile systems is their ability to improve therapeutic outcomes in diseases that exhibit circadian patterns. Conditions such as Asthma, Hypertension, and Rheumatoid Arthritis require drug administration at specific times to achieve maximum effectiveness. PDDS address this need by delivering medication at the most appropriate time, thereby enhancing drug efficacy, reducing side effects, and improving patient compliance. This targeted approach minimizes unnecessary drug exposure and helps in avoiding issues such as drug tolerance and dose-related toxicity.The development of PDDS involves advanced formulation strategies, including time-controlled systems, stimuli-responsive mechanisms, and multiparticulate approaches. These technologies utilize a wide range of polymers and excipients that enable precise control over lag time and drug release profiles. The integration of smart polymers and novel drug carriers has further improved the adaptability and performance of these systems. Additionally, advancements in nanotechnology and material science have opened new avenues for creating more efficient and reliable pulsatile delivery platforms.Despite these advantages, several challenges remain in the widespread application of PDDS. The complexity of formulation and manufacturing processes requires specialized equipment and expertise, which can increase production costs. Ensuring consistent lag time and reproducible drug release profiles is another critical challenge, especially during large-scale manufacturing. Moreover, there is a potential risk of dose dumping if the delivery system fails, which may lead to adverse effects. Regulatory requirements for such advanced systems are also stringent, necessitating extensive testing to ensure safety and efficacy.Looking ahead, the future of pulsatile drug delivery systems appears highly promising. Ongoing research is focused on overcoming current limitations through the development of more robust and cost-effective technologies. The incorporation of personalized medicine approaches, where drug delivery is tailored to individual patient needs and biological rhythms, is expected to further enhance the effectiveness of PDDS. Additionally, the use of digital health tools and real-time monitoring systems may enable more precise control over drug release, paving the way for smarter and more responsive delivery systems.In conclusion, pulsatile drug delivery systems represent a significant advancement in the field of drug delivery, offering a more rational and patient-centric approach to therapy. By aligning drug release with the body's natural rhythms, PDDS have the potential to transform the treatment of various chronic and time-dependent diseases. With continued innovation and research, these systems are likely to play a crucial role in the future of healthcare, contributing to improved therapeutic outcomes and better quality of life for patients.

REFERENCES

1. Sharma, R., Singh, A., & Kumar, S. *Pulsatile drug delivery system: A review*. International Research Journal of Pharmacy, 2012; 3(7): 1–5. (IRJ Pharmacy)
2. Mishra, S., & Mishra, N. *Pulsatile drug delivery system – A review*. International Journal of Recent Advances in Multidisciplinary Topics, 2022; 3(4): 16–18. (IJRAMT)
3. Habeeb, F., & Mohammed, S. *A review on pulsatile drug delivery system*. International Journal of Pharmacy Research & Technology, 2023; 12(2): 10–23. (IJPRT)
4. Venkataswamy, R., & Nallaguntla, L. *Review article on pulsatile drug delivery system*. Asian Journal of Pharmaceutical and Clinical Research, 2021; 14(6): 48–59. (Innovare Academic Sciences)
5. Jain, D., Raturi, R., Jain, V., Bansal, P., & Singh, R. *Recent technologies in pulsatile drug delivery systems*. Biomatter, 2011; 1(1): 57–65. (PMC)
6. Rajput, A., Pingale, P., & Telange, D. *A current era in pulsatile drug delivery system: Drug journey based on chronobiology*. Heliyon. (PMC), 2024.
7. Sharma, G. S., Srikanth, M. V., Uhumwangho, M. U., Kumar, K. S. P., & Murthy, K. V. R. *Recent trends in pulsatile drug delivery systems – A review*. International Journal of Drug Delivery. (International Journal of Drug Delivery), 2010.
8. Prasanna Kumar, P. S. S., & Srinivas, L. (2023). *A review on pulsatile drug delivery systems*. International Journal of Pharmaceutical Sciences and Research. (IJPSR)
9. Valte, Y. B., Mahajan, N. A., Jadhav, V. D., Mogal, R., & Talele, S. *Review on pulsatile drug delivery system*. International Journal for Pharmaceutical Research Scholars, 2015; 4(2): 120–129. (IJPRS)
10. Ravali, V., & Balaji, P. *Pulsatile drug delivery systems: A comprehensive review*. International Journal of Drug Delivery Technology, 2024; 14(1): 463–471. (Vistas)